Axios @axios
Biogen has modified the label of its new Alzheimer’s drug to narrow who should use it. The unusual move so soon after FDA approval raises questions about why it got approved for such a broad population in the first place. https://t.co/Q0b17FLwF8 — PolitiTweet.org